Navigation Links
Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022
Date:8/2/2012

NEW YORK, Aug. 2, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022

http://www.reportlinker.com/p0943308/Pharma-Leader-Series-Top-20-Antibacterial-Drug-Manufacturers-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Antibacterial medicines - discover performance and commercial prospects of companies

How are leading companies in the antibacterial drugs market performing? Visiongain's new report gives you data, analyses and revenue predictions for antibacterial manufacturers.

See how top companies worldwide are performing and where they are heading. You assess their technologies, products and commercial prospects to 2022.

In our study you find analytical profiles for leading antibiotics producers. The work shows product ranges, R&D and sales prospects, with revenue forecasts from 2012 to 2022:• Pfizer• GSK• Merck & Co.• Novartis• Bayer• J&J• Cubist Pharmaceuticals• AstraZeneca• Abbott Laboratories• Medicis• Coverage of 10 other leading manufacturers and four top emerging companies.

You see how antibacterial drug producers compare, discovering how they can compete from 2012. You also find out what will stimulate and restrain business for companies.

The report covers leading pharmaceutical players, specialty companies and emerging organisations. Also, you find companies grouped by region of origin:• The US• Europe• Japan.

Our investigation gives you business research and analysis, including revenue forecasts at world market, submarket and company level to 2022. You find commercial data, predictions, and analyses for leading organisations, their industry and their market area.

Antibacterial drug producers: commercial outlook from 2012

Where is the antibiotics market heading? Many opportunities exist in that industry and market, particularly with the development of new classes of antibacterial drug. In particular, treatments targeting C. difficile and MRSA infections will make a difference to 2022.

Patent expiries will challenge antibiotic manufacturers throughout this decade, with generic pharmaceutical sales prominent and growing. Companies will use product lifecycle management to reduce declines of brands and stimulate their sales, our analysis shows.

What about product launches, new drug classes and expanded indications? The antibacterial R&D pipeline has limitations but holds promise. You find out how leading companies can contribute to our predicted growth and renewal of the market to 2022.

In 2012, more than 50 product candidates are in clinical trials. There are many opportunities for collaborations and in-licensing. Many under-met treatment needs exist.

Which companies are best placed to harness opportunities in the discovery, development, manufacturing and marketing of antibacterial medicines? Our study shows you and explains.

Company analyses, revenue forecasts, R&D and discussions of industry prospects

In visiongain's report you find historical revenues, sales predictions, growth rates and market breakdowns. Also, you see discussions of companies, product portfolios, R&D, commercial news and revenue potentials. You receive 95 tables and 66 charts.

Ten ways Top 20 Antibacterial Drug Manufacturers 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:• Assess 20 leading antibacterial drug manufacturers, discovering their activities and outlooks from 2012• Discover overall world market and submarket revenue forecasts to 2022• Receive analyses of leading companies, seeing revenue forecasts to 2022• View a comparative analysis of trends among antibacterial manufacturers• Find existing revenues and operational data for leading companies• Review pipeline developments, assessing R&D trends and potential• Analyse recent licensing deals and acquisitions• Investigate competition and opportunities influencing sales• Review prospects for emerging companies and antimicrobial specialists• Find out what will stimulate and restrain the industry and market from 2012.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Gain research and analysis on antibacterial drug producers now

Our study is for everybody needing industry and market analyses of antibacterial drug developers and manufacturers. You find data, trends and predictions there. Please order that report now.

Table of Contents 1. Executive Summary

1.1 Leading Antibacterial Drug Manufacturers: Overview of Findings

1.2 Chapter Breakdown

1.3 Research and Analysis Methods

1.4 Scope of this Report

1.4.1 Drugs Considered for this Report

1.4.1.1 Ophthalmic and Dermatologic Antibacterials

1.4.2 The Chinese Antibacterial Drugs Market

1.5 Terminology Used in this Report

2. An Introduction to the Antibacterial Drugs Market2.1 Bacterial Infections and Antibacterial Drugs2.1.1 Gram-Positive and Gram-Negative Infections2.1.2 Treating Bacterial Infections2.2 The Antibacterial Drugs Market 20112.2.1 Leading Classes of Antibacterial Drug2.2.1.1 Cephalosporins2.2.1.2 Penicillins2.2.1.3 Fluoroquinolones2.2.1.4 Macrolides2.2.1.5 Carbapenems2.3 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-20222.3.1 Market Drivers 2012-20222.3.2 Market Restraints 2012-20222.4 Leading Antibacterial Drug Manufacturers in 20112.4.1 Company Comparison2.4.1.1 Broad Product Portfolios2.4.1.2 Regional Focus2.4.1.3 Future of the Antibacterial Drugs Industry

3. The Leading US Big Pharma Antibacterial Drug Manufacturers 2012-2022

3.1 Pfizer

3.1.1 A Long History in Antibacterials

3.1.2 Antibacterial Product Portfolio

3.1.2.1 Dalacin (Clindamycin)

3.1.2.2 Sulperazon (Cefoperazone/Sulbactam)

3.1.2.3 Tygacil (Tigecycline)

3.1.2.4 Unasyn (Ampicillin/Sulbactam)

3.1.2.5 Zithromax (Azithromycin)

3.1.2.6 Zosyn (Piperacillin/Tazobactam)

3.1.2.7 Zyvox (Linezolid)

3.1.3 Antibacterial Revenue 2011

3.1.4 Pipeline

3.1.4.1 Pipeline 2007-2010

3.1.4.2 PNU-100480 (Sutezolid)

3.1.5 Pfizer Antibacterials: SWOT Analysis

3.1.6 Antibacterial Revenue Forecast 2012-2022

3.2 Merck & Co.

3.2.1 Antibacterial Product Portfolio

3.2.1.1 Avelox (Moxifloxacin)

3.2.1.2 Invanz (Ertapenem)

3.2.1.3 Primaxin (Imipenem/Cilastatin)

3.2.2 Antibacterial Revenue 2011

3.2.3 Recent Licensing Deals

3.2.4 Pipeline

3.2.4.1 MK-3415A

3.2.4.2 MK-7655

3.2.5 Merck Antibacterials: SWOT Analysis

3.2.6 Antibacterial Revenue Forecast 2012-2022

3.3 J&J

3.3.1 Antibacterial Product Portfolio

3.3.1.1 Doribax (Doripenem)

3.3.1.2 Levaquin (Levofloxacin)

3.3.2 Antibacterial Revenue 2011

3.3.2.1 Patent Challenges

3.3.3 Decreasing Investment in Antibacterials

3.3.4 Pipeline: TMC207

3.3.5 J&J Antibacterials: SWOT Analysis

3.3.6 Antibacterial Revenue Forecast 2012-2022

3.4 Abbott Laboratories

3.4.1 Antibacterial Product Portfolio

3.4.1.1 Biaxin (Clarithromycin)

3.4.2 Antibacterial Revenue 2011

3.4.3 Abbott Antibacterials: SWOT Analysis

3.4.4 Antibacterial Revenue Forecast 2012-2022

4. The Leading European Big Pharma Antibacterial Drug Manufacturers 2012-20224.1 GSK4.1.1 Antibacterial Product Portfolio4.1.1.1 Augmentin (Amoxicillin/Clavulanate)4.1.1.2 Bactroban (Mupirocin)4.1.1.3 Duac (Clindamycin/Benzoyl Peroxide)4.1.1.4 Fortum (Ceftazidime)4.1.1.5 Zinnat (Cefuroxime)4.1.2 Antibacterial Revenue 20114.1.3 Antibacterials in the US4.1.4 Pipeline4.1.4.1 GSK22510524.1.4.2 GSK13223224.1.5 GSK Antibacterials: SWOT Analysis4.1.6 Antibacterial Revenue Forecast 2012-20224.2 Novartis4.2.1 Antibacterial Product Portfolio4.2.1.1 Ciprodex (Ciprofloxacin/Dexamethasone)4.2.1.2 Cubicin (Daptomycin)4.2.1.3 Moxeza (Moxifloxacin)4.2.1.4 TOBI Podhaler (Tobramycin Inhalation Powder)4.2.1.5 Vigamox (Moxifloxacin)4.2.2 Antibacterial Revenue 20114.2.3 Entering and Exiting Licensing Agreements4.2.4 Pipeline4.2.4.1 Finafloxacin4.2.4.2 LFF5714.2.5 Novartis Antibacterials: SWOT Analysis4.2.6 Antibacterial Revenue Forecast 2012-20224.3 Bayer4.3.1 Antibacterial Product Portfolio4.3.1.1 Avelox (Moxifloxacin)4.3.1.2 Cipro (Ciprofloxacin)4.3.2 Antibacterial Revenue 20114.3.3 Avelox Patent Challenges4.3.4 Bayer and Trius Therapeutics4.3.5 Pipeline4.3.5.1 Ciprofloxacin Inhale4.3.5.2 Amikacin Inhale4.3.6 Bayer Antibacterials: SWOT Analysis4.3.7 Antibacterial Revenue Forecast 2012-20224.4 AstraZeneca4.4.1 Antibacterial Product Portfolio4.4.1.1 Cubicin (Daptomycin)4.4.1.2 Merrem (Meropenem)4.4.1.3 Zinforo (Ceftaroline)4.4.2 Antibacterial Revenue 20114.4.3 AstraZeneca Acquires Novexel4.4.4 Pipeline4.4.4.1 CAZ-AVI4.4.4.2 CEF1044.4.4.3 NXL1034.4.4.4 AZD58474.4.5 AstraZeneca Antibacterials: SWOT Analysis4.4.6 Antibacterial Revenue Forecast 2012-20224.5 Roche4.5.1 Antibacterial Product Portfolio4.5.1.1 Rocephin (Ceftriaxone)4.5.2 Antibacterial Revenue 20114.5.3 Roche Antibacterials: SWOT Analysis4.5.4 Antibacterial Revenue Forecast 2012-2022

5. The Leading Japanese Antibacterial Drug Manufacturers 2012-2022

5.1 Daiichi Sankyo

5.1.1 Antibacterial Product Portfolio

5.1.1.1 Cravit (Levofloxacin)

5.1.2 Antibacterial Revenue 2011

5.1.3 Lifecycle Management

5.1.4 Pipeline

5.1.5 Daiichi Sankyo Antibacterials: SWOT Analysis

5.1.6 Antibacterial Revenue Forecast 2012-2022

5.2 Shionogi & Co

5.2.1 Antibacterial Product Portfolio

5.2.1.1 Finibax (Doripenem)

5.2.1.2 Flomox (Cefcapene)

5.2.1.3 Shionogi Acquires Victory Pharma's Portfolio

5.2.2 Antibacterial Revenue 2011

5.2.3 Lifecycle Management

5.2.4 Patent Challenges

5.2.5 Pipeline

5.2.5.1 S-649266

5.2.6 Shionogi Antibacterials: SWOT Analysis

5.2.7 Antibacterial Revenue Forecast 2012-2022

5.3 Meiji Seika Pharma

5.3.1 Antibacterial Product Portfolio

5.3.1.1 Meiact (Cefditoren)

5.3.2 Antibacterial Revenue 2011

5.3.3 Generic Competition

5.3.4 ME1071

5.3.5 Meiji Seika Pharma Antibacterials: SWOT Analysis

5.3.6 Antibacterial Revenue Forecast 2012-2022

5.4 Astellas Pharma

5.4.1 Antibacterial Product Portfolio

5.4.1.1 Cefzon (Cefdinir)

5.4.1.2 Geninax (Garenoxacin)

5.4.2 Antibacterial Revenue 2011

5.4.3 Astellas and Optimer Pharmaceuticals

5.4.4 Astellas and Theravance

5.4.5 Astellas Pharma Antibacterials: SWOT Analysis

5.4.6 Antibacterial Revenue Forecast 2012-2022

5.5 Dainippon Sumitomo Pharma

5.5.1 Meropen (Meropenem)

5.5.2 Antibacterial Revenue 2011

5.5.3 Licensing Deals

5.5.4 Pipeline

5.5.4.1 DSP-5990

5.5.5 Dainippon Sumitomo Antibacterials: SWOT Analysis

5.5.6 Antibacterial Revenue Forecast 2012-2022

6. The Leading Specialist Antibacterial Drug Manufacturers 2012-20226.1 Cubist Pharmaceuticals6.1.1 Antibacterial Product Portfolio6.1.1.1 Cubicin (Daptomycin)6.1.2 Antibacterial Revenue 20116.1.3 Lifecycle Management6.1.4 Patent Challenges6.1.5 Pipeline6.1.5.1 CXA-2016.1.5.2 CB-3156.1.6 Cubist Antibacterials: SWOT Analysis6.1.7 Antibacterial Revenue Forecast 2012-20226.2 Medicis6.2.1 Antibacterial Product Portfolio6.2.1.1 Solodyn (Minocycline)6.2.1.2 Ziana (Clindamycin/Tretinoin)6.2.2 Antibacterial Revenue 20116.2.3 Patent Extensions and Challenges6.2.4 Pipeline6.2.4.1 GW056.2.5 Medicis Antibacterials: SWOT Analysis6.2.6 Antibacterial Revenue Forecast 2012-20226.3 Salix Pharmaceuticals6.3.1 Xifaxan (Rifamixin)6.3.2 Antibacterial Revenue 20116.3.3 Expanding Approved Indications6.3.4 Salix Pharmaceuticals Antibacterials: SWOT Analysis6.3.5 Antibacterial Revenue Forecast 2012-20226.4 ViroPharma6.4.1 Vancocin (Vancomycin)6.4.2 Antibacterial Revenue 20116.4.3 Generic Competition6.4.4 Pipeline: VP206216.4.5 ViroPharma Antibacterials: SWOT Analysis6.4.6 Antibacterial Revenue Forecast 2012-20226.5 Warner Chilcott6.5.1 Doryx (Doxycycline)6.5.2 Antibacterial Revenue 20116.5.3 Patent Challenges6.5.4 Pipeline6.5.5 Warner Chilcott Antibacterials: SWOT Analysis6.5.6 Antibacterial Revenue Forecast 2012-20226.6 Allergan6.6.1 Antibacterial Product Portfolio6.6.1.1 Zymar (Gatifloxacin)6.6.1.2 Zymaxid (Gatifloxacin)6.6.2 Antibacterial Revenue 20116.6.3 Patent Challenges6.6.4 Allergan Antibacterials: SWOT Analysis6.6.5 Antibacterial Revenue Forecast 2012-2022

7. Emerging Antibacterial Manufacturers

7.1 Pipeline Companies 2012

7.2 Durata Therapeutics

7.2.1 Future Outlook

7.3 Optimer Pharmaceuticals

7.3.1 Future Outlook

7.4 Rib-X Pharmaceuticals

7.4.1 Future Outlook

7.5 Trius Therapeutics

7.5.1 Future Outlook

8. Conclusions8.1 Big Pharma Dominated the Antibacterials Market in 20118.2 The Rise of Generics8.3 Small Companies Can Have a Big Impact on the Industry and Market to 2022

List of Tables

Table 1.1 Currency Exchange Rates, 2011

Table 1.2 Common Abbreviations Used in this Report

Table 2.1 Classification of Common Infection-Causing Bacteria

Table 2.2 Antibacterial Drugs Market by Class, 2010-2011

Table 2.3 Selected Classes of Antibacterial Drug and their Mechanism of Action

Table 2.4 Cephalosporins: Role in the Antibacterial Drugs Market, 2011

Table 2.5 Penicillins: Role in the Antibacterial Drugs Market, 2011

Table 2.6 Fluoroquinolones: Role in the Antibacterial Drugs Market, 2011

Table 2.7 Macrolides: Role in the Antibacterial Drugs Market, 2011

Table 2.8 Carbapenems: Role in the Antibacterial Drugs Market, 2011

Table 2.9 Antibacterial Drugs: Overall World Market and Submarket Forecasting, 2011, 2016 & 2022

Table 2.10 Top 20 Antibacterial Manufacturers by Revenue, 2011

Table 2.11 Antibacterial Revenue as a Share of Pharmaceutical Revenue, 2011

Table 3.1 Pfizer: Key Facts, 2012

Table 3.2 Pfizer: Antibacterial Revenue, 2009-2011

Table 3.3 Pfizer: Antibacterial SWOT Analysis, 2012-2022

Table 3.4 Pfizer: Antibacterial Revenue Forecast, 2011-2022

Table 3.5 Merck & Co: Key Facts, 2012

Table 3.6 Merck & Co: Antibacterial Revenue, 2009-2011

Table 3.7 Merck & Co: Antibacterial SWOT Analysis, 2012-2022

Table 3.8 Merck & Co: Antibacterial Revenue Forecast, 2011-2022

Table 3.9 J&J: Key Facts, 2012

Table 3.10 J&J: Antibacterial Revenue, 2009-2011

Table 3.11 J&J: Antibacterial SWOT Analysis, 2012-2022

Table 3.12 J&J: Antibacterial Revenue Forecast, 2011-2022

Table 3.13 Abbott: Key Facts, 2012

Table 3.14 Abbott: Antibacterial SWOT Analysis, 2012-2022

Table 3.15 Abbott: Antibacterial Revenue Forecast, 2011-2022

Table 4.1 GSK: Key Facts, 2012

Table 4.2 GSK: Antibacterial Revenue, 2010-2011

Table 4.3 Augmentin, Revenue by Region, 2011

Table 4.4 GSK: Antibacterial Drug Pipeline, 2012

Table 4.5 GSK: Antibacterial SWOT Analysis, 2012-2022

Table 4.6 GSK: Antibacterial Revenue Forecast, 2011-2022

Table 4.7 Novartis: Key Facts, 2012

Table 4.8 Novartis: Antibacterial Revenue, 2009-2011

Table 4.9 Novartis: Antibacterial SWOT Analysis, 2012-2022

Table 4.10 Novartis: Antibacterial Revenue Forecast, 2011-2022

Table 4.11 Bayer: Key Facts, 2012

Table 4.12 Bayer: Antibacterial Revenue, 2009-2011

Table 4.13 Avelox: Patent Expiries by Country, 2013-2015

Table 4.14 Bayer: Antibacterial SWOT Analysis, 2012-2022

Table 4.15 Bayer: Antibacterial Revenue Forecast, 2011-2022

Table 4.16 AstraZeneca: Key Facts, 2012

Table 4.17 AstraZeneca: Antibacterial Revenue, 2008-2011

Table 4.18 AstraZeneca: Antibacterial SWOT Analysis, 2012-2022

Table 4.19 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022

Table 4.20 Roche: Key Facts, 2012

Table 4.21 Roche: Antibacterial Revenue, Q1-Q4 2011

Table 4.22 Roche: Antibacterial Revenue by Region, Q1 2012

Table 4.23 Roche: Antibacterial SWOT Analysis, 2012-2022

Table 4.24 Roche: Antibacterial Revenue Forecast, 2011-2022

Table 5.1 Daiichi Sankyo: Key Facts, 2012

Table 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011

Table 5.3 Daiichi Sankyo: Antibacterial SWOT Analysis, 2012-2022

Table 5.4 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022

Table 5.5 Shionogi: Key Facts, 2012

Table 5.6 Shionogi: Antibacterial SWOT Analysis, 2012-2022

Table 5.7 Shionogi: Antibacterial Revenue Forecast, 2011-2022

Table 5.8 Meiji Seika Pharma: Key Facts, 2012

Table 5.9 Meiji Seika Pharma: Antibacterial SWOT Analysis, 2012-2022

Table 5.10 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022

Table 5.11 Astellas Pharma: Key Facts, 2012

Table 5.12 Astellas Pharma: Leading Antibacterial Drug Revenue, FY 2007-2011

Table 5.13 Astellas Pharma: Antibacterial SWOT Analysis, 2012-2022

Table 5.14 Astellas Pharma: Antibacterial Revenue Forecast, 2011-2022

Table 5.15 Dainippon Sumitomo: Key Facts, 2012

Table 5.16 Dainippon Sumitomo: Antibacterial Revenue, FY 2009-2011

Table 5.17 Dainippon Sumitomo: Antibacterial SWOT Analysis, 2012-2022

Table 5.18 Dainippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022

Table 6.1 Cubist Pharmaceuticals: Key Facts, 2012

Table 6.2 Cubist: Antibacterial Revenue, 2008-2011

Table 6.3 Cubicin: International Revenue Payments, 2008-2011

Table 6.4 Cubist: Antibacterial SWOT Analysis, 2012-2022

Table 6.5 Cubist: Antibacterial Revenue Forecast, 2011-2022

Table 6.6 Medicis: Key Facts, 2012

Table 6.7 Medicis: Antibacterial Revenue, 2009-2011

Table 6.8 Medicis: Antibacterial SWOT Analysis, 2012-2022

Table 6.9 Medicis: Antibacterial Revenue Forecast, 2011-2022

Table 6.10 Salix Pharmaceuticals: Key Facts, 2012

Table 6.11 Salix: Antibacterial Revenue, 2009-2011

Table 6.12 Salix: Antibacterial SWOT Analysis, 2012-2022

Table 6.13 Salix: Antibacterial Revenue Forecast, 2011-2022

Table 6.14 ViroPharma: Key Facts, 2012

Table 6.15 ViroPharma: Antibacterial Revenue, 2009-2011

Table 6.16 ViroPharma: Antibacterial SWOT Analysis, 2012-2022

Table 6.17 ViroPharma: Antibacterial Revenue Forecast, 2011-2022

Table 6.18 Warner Chilcott: Key Facts, 2012

Table 6.19 Warner Chilcott: Antibacterial SWOT Analysis, 2012-2022

Table 6.20 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022

Table 6.21 Allergan: Key Facts, 2012

Table 6.22 Allergan: Antibacterial SWOT Analysis, 2012-2022

Table 6.23 Allergan: Antibacterial Revenue Forecast, 2011-2022

Table 7.1 Emerging Companies in the Antibacterial Drugs Market, 2012

Table 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011

List of Figures Figure 2.1 Antibacterial Drugs Market by Class, 2010-2011

Figure 2.2 Antibacterial Drugs: Overall Market Forecast, 2011, 2016 & 2022

Figure 2.3 Antibacterial Drugs Market: Drivers and Restraints, 2012-2022

Figure 2.4 Top 20 Antibacterial Manufacturers by Revenue, 2011

Figure 2.5 Antibacterial Drug Market Entry, 1935-2004

Figure 3.1 Pfizer: Antibacterial Market History, 1944-2009

Figure 3.2 Pfizer: Antibacterial Revenue Shares, 2011

Figure 3.3 Pfizer: Antibacterial Revenue Forecast, 2011-2022

Figure 3.4 Pfizer: Antibacterial Market Share, 2011-2022

Figure 3.5 Merck & Co: Antibacterial Revenue, 2009-2011

Figure 3.6 Merck & Co: Antibacterial Revenue Forecast, 2011-2022

Figure 3.7 Merck & Co: Antibacterial Market Share, 2011-2022

Figure 3.8 J&J: Antibacterial Revenue, 2009-2011

Figure 3.9 J&J: Antibacterial Revenue Forecast, 2011-2022

Figure 3.10 J&J: Antibacterial Market Share, 2011-2022

Figure 3.11 Abbott: Antibacterial Revenue Forecast, 2011-2022

Figure 3.12 Abbott: Antibacterial Market Share, 2011-2022

Figure 4.1 GSK: Antibacterial Revenue Shares, 2011

Figure 4.2 Augmentin, Revenue Shares by Region, 2011

Figure 4.3 GSK: Antibacterial Revenue Forecast, 2011-2022

Figure 4.4 GSK: Antibacterial Market Share, 2011-2022

Figure 4.5 Novartis: Antibacterial Revenue Shares, 2011

Figure 4.6 Novartis: Antibacterial Revenue Forecast, 2011-2022

Figure 4.7 Novartis: Antibacterial Market Share, 2011-2022

Figure 4.8 Bayer: Antibacterial Revenue, 2009-2011

Figure 4.9 Bayer: Antibacterial Revenue Forecast, 2011-2022

Figure 4.10 Bayer: Antibacterial Market Share, 2011-2022

Figure 4.11 AstraZeneca: Antibacterial Sales Revenue, 2008-2011

Figure 4.12 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022

Figure 4.13 AstraZeneca: Antibacterial Market Share, 2011-2022

Figure 4.14 Roche: Antibacterial Revenue Shares, Q1-Q4 2011

Figure 4.15 Roche: Antibacterial Revenue Shares by Region, Q1 2012

Figure 4.16 Roche: Antibacterial Revenue Forecast, 2011-2022

Figure 4.17 Roche: Antibacterial Market Share, 2011-2022

Figure 5.1 Daiichi Sankyo: Antibacterial Market History, 1937-1993

Figure 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011

Figure 5.3 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022

Figure 5.4 Daiichi Sankyo: Antibacterial Market Share, 2011-2022

Figure 5.5 Shionogi: Antibacterial Revenue Forecast, 2011-2022

Figure 5.6 Shionogi: Antibacterial Market Share, 2011-2022

Figure 5.7 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022

Figure 5.8 Meiji Seika Pharma: Antibacterial Market Share, 2011-2022

Figure 5.9 Astellas Pharma: Leading Antibacterial Drug Revenues, FY 2007-2011

Figure 5.10 Astellas Pharma: Antibacterial Revenue Forecast, 2011-2022

Figure 5.11 Astellas Pharma: Antibacterial Market Share, 2011-2022

Figure 5.12 Dainippon Sumitomo: Antibacterial Revenue, FY 2009-2011

Figure 5.13 Dainippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022

Figure 5.14 Dainippon Sumitomo: Antibacterial Market Share, 2011-2022

Figure 6.1 Cubist: Antibacterial Revenue, 2008-2011

Figure 6.2 Cubicin: International Revenue Payments, 2008-2011

Figure 6.3 Cubist: Antibacterial Market Share, 2011-2022

Figure 6.4 Cubist: Antibacterial Revenue Forecast, 2011-2022

Figure 6.5 Medicis: Antibacterial Revenue, 2009-2011

Figure 6.6 Medicis: Antibacterial Revenue Forecast, 2011-2022

Figure 6.7 Medicis: Antibacterial Market Share, 2011-2022

Figure 6.8 Salix: Antibacterial Revenue, 2009-2011

Figure 6.9 Salix: Antibacterial Revenue Forecast, 2011-2022

Figure 6.10 Salix: Antibacterial Market Share, 2011-2022

Figure 6.11 ViroPharma: Antibacterial Revenue, 2009-2011

Figure 6.12 ViroPharma: Antibacterial Revenue Forecast, 2011-2022

Figure 6.13 ViroPharma: Antibacterial Market Share, 2011-2022

Figure 6.14 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022

Figure 6.15 Warner Chilcott: Antibacterial Market Share, 2011-2022

Figure 6.16 Allergan: Antibacterial Revenue Forecast, 2011-2022

Figure 6.17 Allergan: Antibacterial Market Share, 2011-2022

Figure 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011

Companies Listed Abbott Laboratories

Adolor (part of Cubist)

Advanced Life Sciences

AiCuris

Akorn

Alcon Laboratories (a division of Novartis)

Alfa Wassermann

Allergan

Anacor Pharmaceuticals

Apotex

Astellas Pharma

AstraZeneca

Barr Laboratories (part of Teva)

Basilea Pharmaceutica

Bayer

BioRelix

Biovail Laboratories (part of Valeant Pharmaceuticals)

Bristol-Myers Squibb

Calixa Therapeutics (part of Cubist)

Cempra Pharmaceuticals

Chiron (now part of Novartis)

Cornerstone Therapeutics

Cubist Pharmaceuticals

Daiichi Sankyo

Daiichi Sankyo Pharmaceutical (Beijing)

Daiichi Sankyo Pharmaceutical (Shanghai)

Dainippon Pharmaceutical (part of Dainippon Sumitomo)

Dainippon Sumitomo Pharma

DAVA Pharmaceuticals

Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) [US]

Dr Reddy's Laboratories

Durata Therapeutics

Eli Lilly

EMA Committee for Medicinal Products for Human Use (CHMP) [EU]

European Medicines Agency (EMA)

Food and Drug Administration (FDA) [US]

Forest Laboratories

Fujisawa Pharmaceutical (part of Astellas Pharma)

Furiex Pharmaceuticals

Genzyme (part of Sanofi)

Graceway Pharmaceuticals

GSK

Heritage Pharmaceuticals

Hikma Farmaceutica

Hi-Tech Pharmacal

Hospira

Impax Laboratories

Innovative Medicines Initiative [EU]

Itochu Chemical Frontier

Janssen Pharmaceutica (a subsidiary of J&J)

Japan Patent Office (JPO)

Johnson & Johnson (J&J)

Kyorin Pharmaceutical

Lupin

Massachusetts Biologic Laboratories

Mayne Pharma

Medarex (part of Bristol-Myers Squibb)

Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]

Medicis

Medison Pharma

Meiji Holdings (parent company of Meiji Seika Pharma)

Meiji Seika Pharma

Merck & Co.

MerLion Pharmaceuticals

Ministry of Health, Labor and Welfare (MHLW)

Mylan

Mylan Seiyaku (a subsidiary of Mylan)

Nabriva Therapeutics

Nanotherapeutics

National Institute of Allergy and Infectious Diseases (NIAID) [US]

Nektar Therapeutics

Nestlé

NeuTec Pharma (part of Novartis, now closed)

Nichi-Iko Pharmaceutical

Nipro Pharma

Novartis

Novexel (part of AstraZeneca)

Optimer Biotechnology (a subsidiary of Optimer)

Optimer Pharmaceuticals

Ortho-McNeil Pharmaceutical (a subsidiary of J&J)

Paratek Pharmaceuticals

Patent and Trademark Office [US]

Peninsula Pharmaceuticals (part of J&J)

Pfizer

Pharmaceutical Research and Manufacturers of America (PhRMA)

Pharmacia (part of Pfizer)

Pliva (part of Teva)

Proctor & Gamble (P&G)

Protez Pharmaceuticals (part of Novartis, now closed)

Ranbaxy (part of Daiichi Sankyo)

Rib-X Pharmaceuticals

Roche

Rutgers University [US]

Salix Pharmaceuticals

Sandoz (a division of Novartis)

Sanofi

Sawai Pharmaceutical

Schering-Plough (part of Merck & Co)

Scottish Medicines Consortium (SMC)

Senju Pharmaceutical

Sequella

Shantou Meiji Pharmaceuticals (a subsidiary of Meiji Seika Pharma)

Shionogi & Co

Simcere Pharmaceutical Group

State Food and Drug Administration (SFDA) [China]

Stiefel Laboratories (part of GSK)

Strides Arcolab

Sumitomo Pharmaceutical (part of Dainippon Sumitomo)

Sunovion Pharmaceuticals

TaiGen Biotechnology

Taisho Pharmaceutical

Taiyo Yakuhin (Taiyo Pharmaceutical Industry)

Takeda Pharmaceutical

TB Alliance

Tedec-Meiji Farma (a subsidiary of Meiji Seika Pharma)

Tetraphase Pharmaceuticals

Teva Pharmaceutical Industries

The Medicines Company

Theravance

Tibotec Pharmaceuticals (part of Janssen Pharmaceutica)

Towa Pharmaceutical

Toyama Chemical

Trius Therapeutics

Upjohn (part of Pfizer)

Victory Pharma

Vicuron Pharmaceuticals (part of Durata)

ViroPharma

Wakunaga Pharmaceutical

Warner Chilcott

Warner Lambert (part of Pfizer)

Watson Pharmaceuticals

Women First HealthCare

World Health Organization (WHO)

Wyeth Pharmaceuticals (part of Pfizer)

Yale University [US]

Yamanouchi Pharmaceutical (part of Astellas)

Zuellig Pharma

To order this report:Drug and Medication Industry: Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today announced ... full year ended December 31, 2015. ... year for Vanda with the continued growth of HETLIOZ ... HETLIOZ for Non-24," said Mihael H. Polymeropoulos, M.D., Vanda,s ... U.S. product portfolio builds on this success and underscores ...
(Date:2/10/2016)... , February 10, 2016 A new report from ... - states that the Alzheimer,s disease market will more than double from ... at a Compound Annual Growth Rate (CAGR) of 11%. Canada ... Italy , Spain , the UK, and ... during the forecast period. --> Canada , ...
(Date:2/10/2016)... R.I. , Feb. 10, 2016  CVS Health ... to people living in Santa Clara County, ... Meningitis B on the Santa Clara University campus. CVS ... available to protect patients against the disease. Students at ... encouraged to get vaccinated. In addition, anyone who has ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... unveiling its revolutionary new 2.0 version at the International Roofing Expo in Orlando, ... power of the world's most advanced weather technology in the hands of consumers, ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting , a ... partnered with Heart City Health Center to improve access to language ... City Health Center has provided the Elkhart community with access to high quality, ...
(Date:2/10/2016)... NY (PRWEB) , ... February 10, 2016 , ... ... compliance tracking solution, The Guard, to associations of medical professionals throughout the country. ... compliance, including security risk assessments, policies and procedures, employee training, regulatory updates, and ...
(Date:2/10/2016)... ... , ... Emergency rooms provide emergency care to stabilize critical health issues, but ... dental emergencies at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, ... dental emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... ... Valley , announces that his office is now offering a variety of comprehensive ... enhancement, chin enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. ...
Breaking Medicine News(10 mins):